KESON-BROOKES MAIKEN (CLO & Corp. Secretary) sold 33.8% of their position (2.73K shares) of RUBIUS THERAPEUTICS, INC. on the open market
Open‑market sale worth $18.0K — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/1/2022ACC: 0001179110-22-000694
Officer· CLO & Corp. Secretary
Since Nov 2019
+175.52K
Net shares
Net buyer
$18.0K
Total sold
1
Open market trades
0B · 1S
5
Total transactions
186.32K acquired · 10.81K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+8.07K
Price / share
—
Trade value
—
% of position
New position
1/29/2022
0.00→8.07K
Common Stock
Direct
Shares
−2.73K
Price / share
$6.57
Trade value
$17.96K
% of position
33.8%
2/1/2022
8.07K→5.34K
Total
Net shares
+5.34K
Net value
-$17.96K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/29/2022 | M · Option Exercise | +8.07K | — | — | New position | 0.00 | 8.07K |
| Common Stock Direct | 2/1/2022 | S · Sale | −2.73K | $6.57 | $17.96K | 33.8% | 8.07K | 5.34K |
| Total | +5.34K | -$17.96K | ||||||
Derivative Transactions3
Restricted Stock Units
Direct
Converts to
Common Stock
8.07K shares
Shares
−8.07K
Strike price
Held after
24.23K
Exercisable
—
1/29/2022
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
143.75K shares
Shares
+143.75K
Strike price
6.75
Held after
143.75K
Exercisable
—
1/31/2022
Restricted Stock Units
Direct
Converts to
Common Stock
34.50K shares
Shares
+34.50K
Strike price
Held after
34.50K
Exercisable
—
1/31/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Common Stock8.07K shares | 1/29/2022 | M · Option Exercise | −8.07K | — | 24.23K | |
| Stock Option (Right to Buy) Direct | Common Stock143.75K shares | 1/31/2022 | A · Award | +143.75K | 6.75 | — | 143.75K |
| Restricted Stock Units Direct | Common Stock34.50K shares | 1/31/2022 | A · Award | +34.50K | — | 34.50K |